Showing results (91-100 of 110) with videos related to
Sort By:
Pageof 11
Inflammatory Bowel Diseases|November 18, 2021
Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's DiseaseJurij Hanzel, Vipul Jairath, Peter De Cruz, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 16, 2024
Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and EndpointsSailish Honap, Vipul Jairath, Bruce E Sands, et al.Alimentary Pharmacology & Therapeutics|September 27, 2020
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposureEmma Flanagan, Peter R Gibson, Emily K Wright, et al.Gastroenterology|March 27, 2025
Active Inflammatory Bowel Disease on Intestinal Ultrasound During Pregnancy Is Associated With an Increased Risk of Adverse Pregnancy and Neonatal Outcomes Independent of Clinical and Biochemical Disease ActivityRalley E Prentice, Emma K Flanagan, Emily K Wright, et al.World Journal of Gastroenterology|September 3, 2020
Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and OxfordSamba Siva Reddy Pulusu, Ashish Srinivasan, Krupa Krishnaprasad, et al.BMJ Open|July 20, 2024
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trialRobert D Little, Jo McKenzie, Ashish Srinivasan, et al.Cell Death & Disease|June 17, 2026
Impact of BECLIN1 haploinsufficiency on goblet cell function and susceptibility to colitisJuliani Juliani, Sharon Tran, Tiffany J Harris, et al.Journal of Crohn'S & Colitis|February 1, 2018
Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's DiseaseEmily K Wright, Michael A Kamm, Peter De Cruz, et al.Internal Medicine Journal|September 5, 2024
6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapyNatalie Yu, Tanya Lee, Daniel Tassone, et al.Communications Biology|February 20, 2024
BECLIN1 is essential for intestinal homeostasis involving autophagy-independent mechanisms through its function in endocytic traffickingSharon Tran, Juliani Juliani, Tiffany J Harris, et al.Pageof 11